Exhibit 99.1
FOR IMMEDIATE RELEASE
Contact: | Adam C. Derbyshire | Mike Freeman | ||
Senior Vice President and | Executive Director, Investor Relations and | |||
Chief Financial Officer | Corporate Communications | |||
919-862-1000 | 919-862-1000 |
SALIX PHARMACEUTICALS TO PRESENT AT
TWO INVESTMENT CONFERENCES DURING JUNE
RALEIGH, NC, June 5, 2006 - Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Company will present at two health care investment conferences during June 2006. Information on these presentations is provided below:
Pacific Growth Equities 2006 Life Sciences Growth Conference
San Francisco, CA | Monday, June 12 | 6:00 p.m. ET | ||
William Blair & Company 26th Annual Growth Stock Conference | ||||
Chicago, IL | Thursday, June 29 | 12:50 p.m. ET |
Interested parties can access a live audio web cast of these presentations athttp://www.salix.com. A replay of these presentations will be available at the same location.
Salix Pharmaceuticals, Ltd., headquartered in Raleigh, North Carolina, develops and markets prescription pharmaceutical products for the treatment of gastrointestinal diseases. Salix’s strategy is to in-license late-stage or marketed proprietary therapeutic drugs, complete any required development and regulatory submission of these products, and market them through the Company’s gastroenterology specialty sales and marketing team. Salix markets COLAZAL®, XIFAXAN®, VISICOL®, OSMOPREP™, AZASAN®, ANUSOL-HC® and PROCTOCORT®. MOVIPREP® and granulated mesalamine are under development.
Salix trades on the Nasdaq National Market under the ticker symbol “SLXP”.
For more information please contact the Company at 919-862-1000 or visit our web site at www.salix.com. Information on our web site is not incorporated in our SEC filings.